By Klaus Kellings, PhD
BIOCONTRACT SERVICES:
A Supplement to BPJ Volume 3, Issue 3 (May/June 2004)
A major concern for medicinal products of biological origin is the potential risk of contamination with known or unknown viruses. Manufacturers of biopharmaceutical products (such as recombinant proteins and monoclonal antibodies, or products derived from blood, tissue, or urine) are required to assess the ability of their manufacturing process to produce a product that is safe for use in humans…
Citation: Kellings K. Viral and Prion Clearance Studies. BioProcess J, 2004; 3(3, Suppl. 2): S21-27. https://doi.org/10.12665/BCS2.Kellings
Posted online July 19, 2026